Runben Biotechnology Co (603193) Fair Value & Analysis
Consumer Defensive · CN · Market cap 8.7B CNY
Fair value as of: Jul 11, 2026
From 26 valuation models · updated 30 days ago
Fair value updated Jul 11, 2026, revised from ¥15.11 to ¥13.21 (−12.6%) since Jun 24, 2026. Share price +10.4% over the past month.
A solid business, but screening 36% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥16.86). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥9.32 to ¥16.86) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
34‑month range ¥11.95 – ¥41.57 · fair‑value band ¥9.32 – ¥16.86 · the ¥20.79 price screens above the ¥13.21 fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Runben Biotechnology Co (603193) currently trades at ¥20.79, while our model-based Fair Value estimate is ¥13.21, implying the stock looks roughly 36.5% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Runben Biotechnology Co generated revenue of 1.6B CNY at a net margin of 20.6%. Revenue grew 11.3% year over year. It earns a return on equity of 14.7%. The balance sheet holds a net cash position of 105M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥9.32 (bear case) to ¥16.86 (bull case); at ¥20.79, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -36%, 603193 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥26.43) versus Asset-Based (¥3.68). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Runben Biotechnology Co., Ltd. engages in the research, production, and sale of mosquito repellent products, baby care products, and essential oil products. The company sells its products through online channels. Runben Biotechnology Co., Ltd. was founded in 1993 and is based in Guangzhou, China.Runben Biotechnology Co., Ltd.
Full company description
Runben Biotechnology Co., Ltd. engages in the research, production, and sale of mosquito repellent products, baby care products, and essential oil products. The company sells its products through online channels. Runben Biotechnology Co., Ltd. was founded in 1993 and is based in Guangzhou, China.Runben Biotechnology Co., Ltd. operates as a subsidiary of Guangzhou Zhuofan Investment Holding Co., Ltd
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Runben Biotechnology Co reported revenue of ¥1.5B in FY2025 versus ¥582M in FY2021, a compound +27.6%/yr. Reported net income was ¥315M in FY2025, compounding +27.1%/yr from FY2021.
603193 screens 36% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Runben Biotechnology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Runben Biotechnology Co (603193) overvalued or undervalued?
What is the fair value of 603193?
What is the quality score of 603193?
What is the revenue of Runben Biotechnology Co (603193)?
What is the net profit margin of 603193?
Does Runben Biotechnology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Runben Biotechnology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.